Sung, H. et al. World most cancers statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 international locations. CA Most cancers J. Clin. 71, 209–249 (2021).
Begg, A. C., Stewart, F. A. & Vens, C. Methods to enhance radiotherapy with focused medicine. Nat. Rev. Most cancers 11, 239–253 (2011).
Pitroda, S. P., Chmura, S. J. & Weichselbaum, R. R. Integration of radiotherapy and immunotherapy for remedy of oligometastases. Lancet Oncol. 20, e434–e442 (2019).
Nishiga, Y. et al. Radiotherapy together with CD47 blockade elicits a macrophage-mediated abscopal impact. Nat. Most cancers 3, 1351–1366 (2022).
Petroni, G., Cantley, L. C., Santambrogio, L., Formenti, S. C. & Galluzzi, L. Radiotherapy as a instrument to elicit clinically actionable signalling pathways in most cancers. Nat. Rev. Clin. Oncol. 19, 114–131 (2022).
Andratschke, N. et al. European Society for Radiotherapy and Oncology and European Organisation for Analysis and Remedy of Most cancers consensus on re-irradiation: definition, reporting, and medical determination making. Lancet Oncol. 23, e469–e478 (2022).
Fattahi, S. et al. Reirradiation for locoregional recurrent breast most cancers. Adv. Radiat. Oncol. 6, 100640 (2021).
De Ruysscher, D., Faivre-Finn, C., Le Pechoux, C., Peeters, S. & Belderbos, J. Excessive-dose re-irradiation following radical radiotherapy for non-small-cell lung most cancers. Lancet Oncol. 15, e620–e624 (2014).
Beddok, A. et al. Medical and technical challenges of most cancers reirradiation: phrases of knowledge. Crit. Rev. Oncol. Hematol. 174, 103655 (2022).
Liu, Y.-P. et al. Endoscopic surgical procedure in contrast with intensity-modulated radiotherapy in resectable regionally recurrent nasopharyngeal carcinoma: a multicentre, open-label, randomised, managed, section 3 trial. Lancet Oncol. 22, 381–390 (2021).
Xiang, G. et al. Re-irradiation for native primary-recurrence esophageal squamous cell carcinoma handled with IMRT/VMAT. Radiat. Oncol. 18, 114 (2023).
Mahantshetty, U. et al. Reirradiation with superior brachytherapy methods in recurrent GYN cancers. Brachytherapy 22, 753–760 (2023).
Huang, R.-X. & Zhou, P.-Ok. DNA harm response signaling pathways and targets for radiotherapy sensitization in most cancers. Sign Transduct. Goal. Ther. 5, 60 (2020).
Wang, Ok. & Tepper, J. E. Radiation therapy-associated toxicity: etiology, administration, and prevention. CA Most cancers J. Clin. 71, 437–454 (2021).
Yang, Y. et al. ZBP1-MLKL necroptotic signaling potentiates radiation-induced antitumor immunity through intratumoral STING pathway activation. Sci. Adv. 7, eabf6290 (2021).
Tam, S. Y., Wu, V. W. C. & Legislation, H. Ok. W. Affect of autophagy on the efficacy of radiotherapy. Radiat. Oncol. 12, 57 (2017).
Lei, G. et al. The position of ferroptosis in ionizing radiation-induced cell loss of life and tumor suppression. Cell Res. 30, 146–162 (2020).
Han, C. et al. The AIM2 and NLRP3 inflammasomes set off IL-1–mediated antitumor results throughout radiation. Sci. Immunol. 6, eabc6998 (2021).
Chen, H. et al. Radiotherapy modulates tumor cell destiny choices: a assessment. Radiat. Oncol. 17, 196 (2022).
Tsvetkov, P. et al. Copper induces cell loss of life by concentrating on lipoylated TCA cycle proteins. Science 375, 1254–1261 (2022).
Chen, L., Min, J. & Wang, F. Copper homeostasis and cuproptosis in well being and illness. Sign Transduct. Goal. Ther. 7, 378 (2022).
Cobine, P. A. & Brady, D. C. Cuproptosis: mobile and molecular mechanisms underlying copper-induced cell loss of life. Mol. Cell 82, 1786–1787 (2022).
Jin, X.-Ok. et al. Orchestrated copper-based nanoreactor for reworking tumor microenvironment to amplify cuproptosis-mediated anti-tumor immunity in colorectal most cancers. Mater. Immediately 68, 108–124 (2023).
Hasegawa, Ok., Saga, R. & Hosokawa, Y. Radiotherapeutic assessment: acquisition of radioresistance and most cancers stem cell properties through irradiation. Radiat. Environ. Med. 12, 25–36 (2023).
Grey, M. et al. Growth and characterisation of acquired radioresistant breast most cancers cell strains. Radiat. Oncol. 14, 64 (2019).
Zhang, P., et al. Most cancers nanomedicine towards medical translation: obstacles, alternatives, and future prospects. Med 4, 147–167 (2022).
Liu, L., Zhao, C., Miller, J. T. & Li, Y. Mechanistic examine of CO2 photoreduction with H2O on Cu/TiO2 nanocomposites by in situ X-ray absorption and infrared spectroscopies. J. Phys. Chem. C 121, 490–499 (2017).
Wang, D. et al. In situ fashioned Z-scheme graphdiyne heterojunction realizes NIR-photocatalytic oxygen evolution and selective radiosensitization for hypoxic tumors. ACS Nano 16, 21186–21198 (2022).
Ding, Z. et al. Radiotherapy reduces N-oxides for prodrug activation in tumors. J. Am. Chem. Soc. 144, 9458–9464 (2022).
Guo, Z. et al. Radiotherapy-induced cleavage of quaternary ammonium teams prompts prodrugs in tumors. Angew. Chem. Int. Ed. 61, e202205014 (2022).
Zhang, C. et al. Tumor microenvironment-responsive Cu2(OH)PO4 nanocrystals for selective and controllable radiosentization through the X-ray-triggered Fenton-like response. Nano Lett. 19, 1749–1757 (2019).
Wang, L., Jiang, N., Xu, H., Luo, Y. & Zhang, T. Hint Cu(II)-mediated selective oxidation of benzothiazole: the predominance of sequential Cu(II)–Cu(I)–Cu(III) valence transition and dissolved oxygen. Environ. Sci. Technol. 57, 12523–12533 (2023).
Zeng, L., Miller, E. W., Pralle, A., Isacoff, E. Y. & Chang, C. J. A selective turn-on fluorescent sensor for imaging copper in residing cells. J. Am. Chem. Soc. 128, 10–11 (2006).
Liu, X. et al. Actin cytoskeleton vulnerability to disulfide stress mediates disulfidptosis. Nat. Cell Biol. 25, 404–414 (2023).
Xu, W. et al. Tumor microenvironment responsive hole nanoplatform for triple amplification of oxidative stress to reinforce cuproptosis-based synergistic most cancers remedy. Adv. Healthc. Mater. 12, 2202949 (2023).
Zhou, J. et al. Photothermally triggered copper payload launch for cuproptosis‐promoted most cancers synergistic remedy. Angew. Chem. Int. Ed. 62, e202213922 (2023).
Guo, B. et al. Cuproptosis induced by ROS responsive nanoparticles with elesclomol and copper mixed with αPD-L1 for enhanced most cancers immunotherapy. Adv. Mater. 35, 2212267 (2023).
Tang, D., Chen, X. & Kroemer, G. Cuproptosis: a copper-triggered modality of mitochondrial cell loss of life. Cell Res. 32, 417–418 (2022).
Zhao, B. et al. Photocatalysis-mediated drug-free sustainable most cancers remedy utilizing nanocatalyst. Nat. Commun. 12, 1345 (2021).
Ning, S. et al. Sort-I AIE photosensitizer loaded biomimetic system boosting cuproptosis to inhibit breast most cancers metastasis and rechallenge. ACS Nano 17, 10206–10217 (2023).
Chan, L. et al. Cuproptosis‐pushed enhancement of thermotherapy by sequentially response Cu2‐xSe through copper chemical transition. Adv. Funct. Mater. 33, 2302054 (2023).
Xu, W. et al. A hole amorphous bimetal natural framework for synergistic cuproptosis/ferroptosis/apoptosis anticancer remedy through disrupting intracellular redox homeostasis and copper/iron metabolisms. Adv. Funct. Mater. 32, 2205013 (2022).
Demaria, O. et al. Harnessing innate immunity in most cancers remedy. Nature 574, 45–56 (2019).
Kroemer, G., Galassi, C., Zitvogel, L. & Galluzzi, L. Immunogenic cell stress and loss of life. Nat. Immunol. 23, 487–500 (2022).
Fucikova, J. et al. Detection of immunogenic cell loss of life and its relevance for most cancers remedy. Cell Dying Dis. 11, 1013 (2020).
Liao, Y. et al. Piezoelectric supplies for synergistic piezo- and radio-catalytic tumor remedy. Nano Immediately 44, 101510 (2022).
Ni, Ok. et al. Synergistic checkpoint-blockade and radiotherapy–radiodynamic remedy through an immunomodulatory nanoscale metallic–natural framework. Nat. Biomed. Eng. 6, 144–156 (2022).
Huang, Z. et al. Nanoscale coordination polymers induce immunogenic cell loss of life by amplifying radiation remedy mediated oxidative stress. Nat. Commun. 12, 145 (2021).
Min, Y. et al. Antigen-capturing nanoparticles enhance the abscopal impact and most cancers immunotherapy. Nat. Nanotechnol. 12, 877–882 (2017).
Melo, L. M. N., Lesner, N. P., Sabatier, M., Ubellacker, J. M. & Tasdogan, A. Rising metabolomic instruments to review most cancers metastasis. Tendencies Most cancers 8, 988–1001 (2022).
Li, H. et al. Nanomedicine embraces most cancers radio-immunotherapy: mechanism, design, current advances, and medical translation. Chem. Soc. Rev. 52, 47–96 (2023).
Twyman-Saint Victor, C. et al. Radiation and twin checkpoint blockade activate non-redundant immune mechanisms in most cancers. Nature 520, 373–377 (2015).
Franken, N. A. P., Rodermond, H. M., Stap, J., Haveman, J. & Van Bree, C. Clonogenic assay of cells in vitro. Nat. Protoc. 1, 2315–2319 (2006).
